Over the last 10 years, protein-protein interactions (PPIs) have shown increasing potential as new therapeutic targets. As a consequence, PPIs are today the most screened target class in high-throughput screening (HTS). The development of broad chemical libraries dedicated to these particular targets is essential; however, the chemical space associated with this 'high-hanging fruit' is still under debate. Here, we analyse the properties of 40 non-redundant small molecules present in the 2P2I database (http://2p2idb.cnrs-mrs.fr/) to define a general profile of orthosteric inhibitors and propose an original protocol to filter general screening libraries using a support vector machine (SVM) with 11 standard DRAGON molecular descriptors. The filtering protocol has been validated using external datasets from PubChem BioAssay and results from in-house screening campaigns. This external blind validation demonstrated the ability of the SVM model to reduce the size of the filtered chemical library by eliminating up to 96% of the compounds as well as enhancing the proportion of active compounds by up to a factor of 8. We believe that the resulting chemical space identified in this paper will provide the scientific community with a concrete support to search for PPI inhibitors during HTS campaigns.
Introduction
Protein -protein interactions (PPIs) play a central role in many cellular processes, including signal transduction, cell adhesion, cell proliferation, growth, differentiation, viral self-assembly and programmed cell death (see reviews [1] [2] [3] ). These interactions are involved in numerous pathways, including diseases, different stages of cancer development and host-pathogen interactions. Therefore, the modulation of these networks of transient interactions is a promising therapeutic strategy. PPIs are becoming more accepted as potential drug targets despite the long-held assumption that they were poorly druggable [4] . Modulators of these original interactions are likely to lead to the next generation of highly innovative drugs that should reach the market in the next decade. However, the in silico design of such compounds remains challenging [5] [6] [7] [8] [9] [10] [11] . PPI modulators (PPIMs) can be activators or inhibitors of the interaction, in this work the term 'modulators' only refers to PPI inhibitors.
The identification of hot spots at the interface of PPIs [12] has given a rationale for the possible disruption of protein-protein complexes with small molecules. Since then, there have been an increasing number of studies reporting the disruption of PPIs by small molecules [13] [14] [15] [16] [17] [18] [19] [20] . Consequently, these successes have opened the way to the development of strategies to assess the druggability (or more appropriately ligandability) of protein-protein complexes [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] .
A number of strategies have been used to conceive non-peptidic PPI inhibitors (for reviews, see [2, 9, 10, 15, 19] ). Two of the main approaches involve the use of small molecule chemical libraries through high-throughput screening (HTS) and fragment libraries using fragment-based drug discovery (FBDD) [34] [35] [36] [37] [38] [39] . There are usually few small hydrophobic pockets at the protein-protein interface [21] that can each be filled with fragments, therefore FBDD is a very promising and efficient approach in the case of PPIs. However, one the major hurdle/challenge of this approach remains how to combine the low-affinity fragments to conceive high-affinity drug leads. In this research article, we only focus on the conception of small molecule chemical libraries dedicated to PPIs and we do not consider fragments.
Despite the progress in PPI drug discovery in the last decade, the success rate of finding hit compounds in HTS campaigns using small molecule compounds remains generally very low [40] . This low success rate suggests that most of the available chemical libraries are not appropriate for screening PPI targets. The poor suitability of commercial libraries demonstrates the need to design targeted chemical libraries that are dedicated to this particular chemical space [41] . These targeted libraries would accelerate and reduce the cost of screening campaigns by enhancing the number of hits while reducing the number of compounds tested which could help in bringing pharmaceutical companies back on target [42] . One way to achieve this goal is to design filtering algorithms for large chemical libraries that remove compounds that are unlikely to disrupt PPI interfaces while preserving a large number of potential disruptors in the selected subset. Several studies have focused on the chemical properties of known PPI inhibitors [1, 43, 44] . A general profile has been defined for these PPI inhibitors by compiling a collection of known PPI inhibitors and comparing them to other drugs. The authors found that PPI inhibitors are generally larger and more hydrophobic compared with other small molecule -protein complexes. They tend to form fewer hydrogen bonds and present more aromatic and hydrophobic interactions at the protein -ligand interface.
Decision tree methods have also been used to design PPI-inhibitor-focused libraries [45] [46] [47] [48] [49] . However, these studies focused on a set of validated drug-like PPI inhibitors, regardless of their modes of inhibition. Small molecule PPI inhibitors can be classified as orthosteric or allosteric modulators, depending upon their modes of interaction [50] . The former compete directly with hot spots at the interface [12] , while the latter bind to a cavity away from the interface, which usually prevents the conformational changes necessary for binding to the protein partner. In addition, small molecules in vivo can prevent the formation of a proteinprotein complex through non-direct mechanisms. To target the PPI inhibitors that directly interfere with the interface of protein -protein complexes, we focused on cases where the three-dimensional structures of both the protein -protein and protein-ligand complexes have been characterized. This work resulted in the freely accessible 2P2I DB structural database (structural database dedicated to the inhibition of protein -protein interactions; http://2p2idb.cnrs-mrs.fr) [23] .
In this research article, we analysed the properties of 40 non-redundant small molecules found in 2P2I DB to define a general profile of orthosteric inhibitors. We propose an original protocol, 2P2I HUNTER , to filter general screening libraries with a machine-learning approach. The models were built using a support vector machine (SVM) with 11 standard DRAGON molecular descriptors. The best models were externally tested on the only two representative PPI bioassays from the publicly available PubChem Bioassay database for biological activities of small molecules (http://pubchem. ncbi.nlm.nih.gov/). This external blind validation demonstrated the ability of the SVM model to reduce the size of the filtered chemical library by eliminating up to 96% of the compounds as well as enhancing the proportion of active compounds by up to a factor of 8.
Results and discussion

Selection of the training dataset
We have developed the 2P2I structural database of all known protein -protein and protein -inhibitor complexes for which both three-dimensional structures are available [23] . Since the first release of the database in 2010, 2P2I DB has been updated to v. 1.0 (http://2p2idb.cnrs-mrs.fr/2p2i_db.html).
The database currently contains 14 protein-protein complexes corresponding to various types of interfaces, including helix-based, beta-strand, mixed-folding (helix/beta strand) and loop-binding groove domains [51] . We have proposed a classification of these complexes into two main classes based on the type of interface; Class I, corresponding to proteinpeptide complexes and Class II, corresponding to more globular protein-protein complexes contain [33] . Both classes are composed of seven protein-protein families. As 2P2I DB grows, our goal is to classify protein-protein complexes based on the characteristics of their interface, to develop specific scoring functions and to associate a dedicated chemical library to each type of interface. However, data currently available do not allow this type of approach yet owing to the small number of protein-protein and protein-inhibitor complexes with a known three-dimensional structure. Although, the 14 complexes in 2P2I DB possess different types of interfaces, they still exhibit some common features that are reflected in the properties of the small molecule inhibitors, for example the presence of small hydrophobic pockets, that are not linearly distributed. It is important to note that all other published studies dealing with the analysis of the properties of PPIMs and the conception of PPItargeted chemical libraries have used all available PPI inhibitors regardless of their mode of action [20, [44] [45] [46] [47] [48] . Especially, they did not differentiate between orthosteric and allosteric inhibitors which are likely to possess quite different properties.
There are currently 52 small molecule orthosteric inhibitors in the 2P2I database [51] . To guarantee the structural diversity of the compounds, the small molecule orthosteric inhibitors in 2P2I DB were clustered with a Tanimoto similarity criterion of 0.8 (OptiSim algorithm implemented in the Tripos package) leading to 40 non-redundant molecules, which were used as the positive set in our learning approach (see the two-dimensional representation of molecules in the electronic supplementary material, figure S1 ). The selection of decoy molecules ( presumed to be inactive against PPI targets) is more complicated owing to the impossibility of testing the compounds against all known PPI targets. The human 'interactome' is estimated to number between approximately 130 000 [52] and 650 000 [53] PPIs. To be definitively validated as a non-PPI inhibitor, a compound would have to be tested against a significant number of these protein -protein complexes. The aim of this work is to develop a filtration tool that is able to increase the hit rate in a screening campaign (i.e. to accelerate and reduce the cost of hit finding in a screening campaign). This aim can rsif.royalsocietypublishing.org J. R. Soc. Interface 11: 20130860 be achieved by either selecting the maximum number of true PPI inhibitors in a screening library or removing the maximum number of non-PPI inhibitors (or a combination of both). The next step involved the selection of a decoy dataset consisting of small drug-like molecules representative of commercial chemical libraries. We thus compared the molecular properties of the validated PPI inhibitors with several diverse chemical libraries (such as NCI Diversity set II, DiverSet from ChemBridge, LifeChemical and FDA approved) and we analysed the ability to discriminate between compounds from the positive training dataset and the different libraries. We selected NCI Diversity set II (1364 compounds) as a decoy because it allowed a better separation of the two datasets in t-test validations and preliminary SVM models (data not shown). As for the positive dataset, decoy compounds were clustered to remove redundancy with Tanimoto similarity comparisons of the UNITY fingerprints. Molecules with reactive groups and detergent compounds as well as those for which it was not possible to calculate all molecular descriptors were removed from the decoy dataset (see Material and methods). The final training dataset selected for the SVM approach contained 40 active (orthosteric PPI inhibitors) and 1018 inactive (non-PPI inhibitors) compounds (see electronic supplementary material, table S1). The chemical diversity and overlapping of the training dataset were assessed using a large set of two-dimensional BCUT metrics (see electronic supplementary material, figure S2 ). As expected, this analysis demonstrated the lack of redundancy within each dataset. In addition, compounds from the positive dataset covered most of the chemical space defined by the decoy.
2P2I HUNTER : a filtering protocol to design proteinprotein interaction libraries
To gain further insight into the selection of PPI inhibitors, SVM models were built and optimized based on the positive dataset and decoy described above. We used a classification SVM with a radial Gaussian basis (RGB) kernel and fivefold internal cross-validation. After comparing the spread of values and various molecular properties between the positive dataset and decoy, we performed t-tests to select standard molecular descriptors for the partial separation of the positive dataset and decoy. The final 11 molecular descriptors selected are listed in the electronic supplementary material , table S2 . The SVM models were optimized using a receiver operating characteristic (ROC) curve value to counter the imbalance ratio of active/inactive (1/25) [54] . This choice (a compromise between specificity and sensitivity) was also guided by the characteristics of the desired filtration tool. The entire dataset was randomly split into five folds; four folds were used for training, and the fifth fold was used for testing. This process was repeated 30 times, and the final average performance was calculated. The best selected model resulted in 98% accuracy, 100% specificity and 62.5% sensitivity (tables 1 and 2). To validate the robustness of the model, the PPI classification properties (active or not) of the 40 orthosteric PPI inhibitors from the positive dataset were randomly reordered (by scrambling). The average ROC AUC, obtained over 20 successive Y-scrambling runs, decreased from 0.96 with the actual activity labels to approximately 0.6 (the random threshold value was 0.5).
PCA analyses of the training dataset
Separation of the positive and decoy compounds in the training dataset using the 11 molecular descriptors was assessed using PCA analyses (figure 1a). Unlike the BCUT metrics, the 11 DRAGON descriptors separated the true PPIMs and decoy molecules (figure 1a and electronic supplementary material, figure S1 ). The first two principal components accounted for more than 72% of the entire data variance. The most significant descriptors in the first PCA dimension corresponded to the number of hydrogen bond donors and acceptors (figure 1b). Topological polar surface area and molecular weight (MW) also had important contributions. The second dimension of the PCA analysis was dominated by ALogP, the level of unsaturation and the number of rings. Altogether, these principal components represented the four parameters that define rule of 4 ('Ro4') as defined previously [5, 55] . MW, ALogP, number of rings and number of hydrogen bond acceptors all significantly contributed to the first or second principal component, as shown in figure 1b.
Most compounds from the decoy were clustered together (black ellipse in figure 1 ). The 40 orthosteric PPI inhibitors selected as the positive dataset occupied three cluster regions in the PCA representation. Interestingly, a correlation could be observed between compound clustering and the protein complexes targeted by the inhibitors. Eight PPI compounds were located in the main region occupied by the decoy. They mainly corresponded to low MW compounds targeting ZipA/FtsZ and HIV-1 integrase LEDGF/p75 complexes (average MW ¼ 370.9 + 44.4 g mol 21 ) . It is worth pointing out that these inhibitors bind in a non-conventional way to their protein target. ZipA/FtsZ inhibitors exhibit low binding affinity constants (K d 10 -100 mM) and they appear to sit on the protein surface in the X-ray structure [21, 44, 56] . Their binding is achieved through hydrophobic contacts without any polar interaction between the ligand and the protein We decided not to remove these non-conventional compounds from the learning dataset although it would have improved the global statistics of the models. The remaining orthosteric PPI compounds were mainly split between two similarly populated regions (red ellipses in figure 1 ) that showed little overlap with the decoy. The 14 compounds from cluster 1 (bottom red ellipse in figure 1 ) corresponded almost exclusively to inhibitors of the XIAP and IL2 families. , number of rings (5.5+0.9) and fewer hydrogen bond donors (1.5+1.1). Only one of these 17 compounds was not 'Ro4' compliant. Finally, the XIAP/SMAC bivalent inhibitor (CZ3) lies outside these clusters mainly owing to its high MW (971.4 g mol
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) and number of hydrogen bond acceptors [16] . It is worth mentioning that the monomeric compound (MW ¼ 486.7) is also an inhibitor of the interaction, although slightly less efficient [59] . figure S3 ). We first selected (using a keyword search) the series of bioassays grouped by AID summaries that correspond to PPIs. This search found 28 different bioassays (see electronic supplementary material, figure S3 ). Among these assays, we selected hits for which both primary and secondary (dose-response) assays were available (17 bioassays). At this stage, the bioassays were manually inspected and only those corresponding to PPIs were selected (five bioassays). Only in vitro bioassays were selected (three bioassays) to ensure that the inactivity was not owing to membrane barrier crossing, cytotoxicity effects or metabolic conversion of the compounds in the cell. The SVM model is a general model; therefore, we did not use bioassays dedicated to the development of target-specific inhibitors. For example, several bioassays correspond to the development of selective inhibitors of myeloid cell leukaemia sequence 1 (MCL1). In this series of bioassays, the authors selected compounds that are not active on other Bcl-2 proteins, for example Bcl-XL. Because our model was trained with modulators of the Bcl-XL family, it is not expected to perform well for these types of bioassays. Overall, two sets of bioassays were selected (AID 1645 and 1683; electronic supplementary material, figure S3 and table S3). AID 1496 and 1438 correspond to the primary and secondary HTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and the Core-binding factor, beta subunit. AID 1531 (primary screen) and 1892/1897 (secondary screens) correspond to the HTS Assay for modulators of MEK Kinase PB1 Domain interactions via MEKK5.
External validation of the support vector machine model: bioassay selection
Blind validation of 2P2I HUNTER with selected bioassays
The ability to enhance hit rates in screening campaigns with the 'Ro4' and the best SVM model as filtering tools was tested rsif.royalsocietypublishing.org J. R. Soc. Interface 11: 20130860 on the two HTS compound bioassays selected from PubChem. The overall performances for the different models are summarized in table 3. Confusion matrices, ROC curves and overall performances (in terms of accuracy, sensitivity and specificity) are shown in figure 2 . To quantify the performance of the SVM approach, we used the enrichment factor metric, which compares the performance of the model to the performance expected if the compounds were randomly selected. The enrichment factor is given by the ratio between the hit rate obtained with the entire chemical library and the hit rate for the filtered library. Based on this metric, we observed a significant improvement of the HTS performances for both bioassays. With both external validation datasets, the application of the 'Ro4' allows approximately 20% of the compounds from the starting chemical library to be selected, representing a significantly improved hit rate (enrichment factor of approx. 3). Therefore, the 'Ro4' constitutes a simple and fast method of designing chemical libraries enriched in PPI inhibitors. The SVM model showed high accuracy and specificity with values of 0.96 for both validation datasets, compared to 0.8 for the 'Ro4' filtering (figure 2). Although these high values are probably related to the relatively imbalanced ratio of active and inactive compounds in the training dataset, they indicate that the SVM model can be used as a highly efficient tool for removing non-PPI compounds from large screening libraries. The true positive rate (as measured by the sensitivity) was lower for the SVM, with values of 9% and 36% for AID 1496 and 1531, respectively. The 'Ro4' exhibited a higher sensitivity than the SVM model (53% and 55% for AID 1496 and 1531, respectively), which shows that it is able to retrieve more true active compounds in absolute numbers. However, the SVM model is much more stringent. This model was able to eliminate a large number of non-PPI compounds, leading to an increase in the hit rate of a factor up to 8. It is important to point out that none of the active molecules were present in the training dataset. The distributions of MW, number of rings (#Rings) and number of hydrogen bond acceptors (#HBA) in the positive dataset and the two validation datasets were compared to further analyse the performance of the SVM rsif.royalsocietypublishing.org J. R. Soc. Interface 11: 20130860
tool (see electronic supplementary material, figure S4 ). As expected, the active molecules with low MW were poorly predicted by the SVM model. It should be noted that although molecules in validation bioassays are classified in a binary manner as active or inactive, the activity described in these bioassays is covering a large binding affinity range (from 0.14 to more than 50 mM). A significant amount of the active molecules in both bioassays could almost be considered as fragments (MW 300 g mol
21
) and are outside the scope of this SVM model. A similar distribution was observed for the number of rings in the active molecules and those selected by the SVM model for both validation bioassays. However, in the case of AID1531, a series of 12 molecules were poorly predicted owing to their high MWs (average MW ¼ 1063.1+42.0) and high number of rings (average #Rings ¼ 8.1+1.2). Finally, the distribution of #HBA for most active molecules in AID1531 was downshifted to lower values compared with the distribution of selected molecules which could account for the non-selection of some active compounds.
Interestingly, most true positive compounds selected by the SVM model followed the 'Ro4' (69% in the case of AID1531 and 100% in the case of AID1496). This finding prompted us to combine the two approaches to refine the filtering process. We applied the 'Ro4' filtering tool to the compounds selected by the SVM model. The results in table 3 demonstrated a slight increase in the hit rate compared with the SVM model owing to a smaller number of selected compounds and almost the same number of true positive PPI inhibitors predicted. Molecules selected by the SVM model for both validation bioassays overlapped with the region defined by the positive dataset as shown by PCA analysis (see electronic supplementary material, figure S5 ).
AID1531 led to better overall enrichment factors, indicating that the active compounds in this bioassay were closer to the 2P2I chemical space, as observed in the representation of the two principal components (see electronic supplementary material, figure S5 ). X-ray structures were available for the unbound Runx1/Runt domain (PDB code 1EAN) and the core-binding factor beta (PDB code 2JHB), which corresponds to the protein targets in bioassay AID1496. However, no structural information was available for the protein targets in AID1531 or the protein -protein complexes. Therefore, we were not able to compare the MEKKK2/MEKK5 and RuntX/CBFb complexes to those present in 2P2I DB to determine whether the difference between the two bioassays was related to the structure of the protein -protein interfaces.
Chemical diversity of selected molecules
The structural diversity of the molecules selected with the SVM model was checked (using a Tanimoto index of 0.8), and on average they did not share the same scaffold. In the case of AID1531, the 35 true-positive compounds corresponded to 26 different classes after the similarity clustering (comparable to the diversity of the active molecules); whereas all four truepositive compounds in AID1496 were dissimilar, indicating that this SVM protocol did not retrieve a series of compounds from the same family.
Blind validation with in-house PPI bioassays
The overall performance of 2P2I HUNTER was also assessed using results from in-house PPI bioassays. Prior to this study, a high-throughput screen against a PPI target was performed by the industrial partner involved in this study to identify PPIMs using a FRET assay in the primary screening and IC50 for the secondary dose-response confirmatory screening, which led to a low success rate of 0.004% (table 4) . Application of the SVM protocol to the entire collection of compounds used in the HTS campaign selected 8.5% of the molecules, corresponding to the filtered library (tables 4 and 5). A significant improvement was observed in the hit rate for this resulting filtered chemical library (0.025%), which corresponds to an enrichment factor of 5.9. It is especially noteworthy that 50% of the active compounds found in the HTS campaign were present in the filtered library. In a parallel approach, results from a large series of in-house protein-protein and protein-peptiderelated primary or dose-response screenings were pooled together, which allowed us to search for PPIMs in the filtered library (table 5) . In particular, we looked for evidence of activity in PPI modulation bioassays for each compound in the filtered library. We were not able to calculate enrichment factors because the bioassays were not conducted on the entire in-house non-filtered collection of compounds for comparison. However, we estimated the percentage of true PPIMs in the filtered library (table 5), which ranged from 0.6 to 4.1%. Not all of the compounds in the filtered library have been tested in the various bioassays, so the percentages are underestimated. A higher percentage of predicted PPIMs was observed for protein-peptide-related bioassays, which could indicate that the SVM protocol performs better for these families of targets.
Applicability domain of 2P2I HUNTER support vector machine filtration tool
The SVM filtration tool was applied to a set of 25 chemical libraries representing more the 8.3 M compounds and its applicability domain was discussed in details previously [55] . Interestingly, compared with all other chemical libraries tested, the percentage of selected compounds was higher for the PPI library from ChemDiv (figure 3a). Selected compounds Percentage of molecules selected by the model at a probability threshold of 0.5. c Hit rate of the model. rsif.royalsocietypublishing.org J. R. Soc. Interface 11: 20130860 from the Eccentric subset of ChemDiv (83.1%) cover almost the entire PPI chemical space described by our SVM model (figure 3b). This subset contains approximately 7000 compounds that are grouped together based on their original scaffolds outside of the field of (hetero)aromatic systems and their low toxicity [62] . The compounds from the Cyclic Ugi subset overlap with 50% of the PPI inhibitors in 2P2I database (figure 3c). The compounds selected from the mdm2-focused subset cover a smaller chemical space that encompasses most of the mdm2/p53 inhibitors found in 2P2I DB ( figure 3d) . Thus, the 2P2I chemical space that we identified is able to select new and/or unusual aromatic scaffolds that exhibit low toxicity and lie outside the field of extensively used benzenoid and heteroaromatic ring systems [62] . The distributions of MW, #Ring, #HBA have been compared for ChemDiv PPI, Eccentric and three other representative chemical libraries (see electronic supplementary material, figure S6 ). Although, libraries rich in high MW compounds also corresponded to libraries with a higher percentage of selected molecules by the SVM tool, the correlation was not linear. There was a clear shift towards high MW in the case of the Eccentric subset for which 94.5% of the molecules have an MW 400 g mol 21 and 83.1% of the molecules are selected.
ChemDivPPI and IBScreen libraries contain 64.1% and 48.8% of molecules with MW 400 g mol
21
, respectively. However, the number of selected molecules for these two libraries is similar and much lower than that for the Eccentric subset (10.8% and 11.2%, respectively). Not surprisingly, libraries rich in low MW compounds also corresponded to a lower percentage of selected molecules. Maybridge and Otava collections of compounds contain 19.4% and 9.6% compounds with MW 400, respectively, however a similar percentage of molecules is selected by the SVM model (1.1% and 1.2%, respectively). Concerning the number of rings, a weaker correlation was observed. Overall, libraries containing molecules with a higher number of rings correspond to the libraries with high percentages of selected compounds by the SVM tool. However, when comparing among themselves libraries containing molecules with a high number of rings such as Eccentric, ChemDivPPI and IBScreen, no correlation was observed between the high number of rings and the percentage of selected molecules (see electronic supplementary material, figure S6) . Finally, the distribution of HBA seemed slightly shifted towards lower values for libraries with lower percentage of selected molecules.
Conclusion
In the postgenomic era, the identification of complete networks of PPIs within a cell has contributed to major breakthroughs in understanding biological pathways, hostpathogen interactions and cancer development. This work has also led to the identification of novel therapeutic drug targets [63] . PPIs represent a promising new class of attractive therapeutic targets and correspond to the most screened rsif.royalsocietypublishing.org J. R. Soc. Interface 11: 20130860 target in HTS today (93% screening) followed by kinases (82% screening) according to a recent survey [64] . However, this class of targets is still considered to be extremely difficult for targeting by small molecules, owing to the structural characteristics of the interfaces. Specific strategies are needed to tackle this particularly challenging class of drug targets. Successes in drug discovery developments against PPI targets face two major issues, druggability assessment (or target selection) and adequacy of the chemical libraries used for screening. Our strategy to address these issues was to focus on orthosteric PPIMs. Therefore, we only considered PPIs for which structural information was available to validate that the inhibitor was interacting at the interface. We have recently developed the hand-curated structural 2P2I database by collecting information about protein -protein interfaces for which both the protein -protein and protein -inhibitor complexes have been structurally characterized. We identified key descriptors of PPIs with known inhibitors [23] . Although this database is currently rather small, a recent update has resulted in an increase of almost 30% of small molecules orthosteric inhibitors. As the database is growing, our goal is to cluster protein -protein complexes into different structural families based on the properties of the interface and to associate a dedicated chemical library with each type of interface.
Here, we report the analysis and characterization of the chemical space of PPI orthosteric inhibitors present in the 2P2I database (http://2p2idb.cnrs-mrs.fr) to provide tools to build focused chemical libraries dedicated to PPI targets from large screening libraries. PPI inhibitors are sometimes not considered to be potential drug-like compounds owing to their high MWs and hydrophobicity. However, more than 60% of the active compounds in 2P2I DB are compliant with Lipinski 'rule-of-five' [65] and 65% follow Veber rules for bioavability [66] demonstrating that they could possess ADME properties that are compatible with further developments as oral drugs and that rules defined in this article to characterize PPI inhibitors and drug-likeness are not mutually exclusive.
We have developed a general protocol to filter chemical libraries using SVM approaches. This 2P2I HUNTER filtration tool has been validated using external bioassays from PubChem and in-house screening results. Our tool demonstrated the potential to significantly increase success rates, leading to enrichment factors of up to 8. The protocol was applied to a set of 25 commercial libraries from the major providers [55] . In all cases, the tool dramatically decreased the size of the original libraries compared with the resulting focused libraries (on average, 94% of the compounds were removed from the original libraries). However, more than 80% of the 7076 compounds from the ChemDiv Eccentric PPI library were selected as putative PPIMs by the 2P2I HUNTER filtration tool (see [55] for a detailed analysis of the chemical space).
In general, only a limited number of molecules can be tested in screening campaigns in academic institutions (and increasingly in pharmaceutical companies as well). The 2P2I HUNTER protocol has been used to build in-house chemical libraries of small size [55] that will be tested on PPI targets, covering a wide range of biological and chemical spaces including the well-studied mdm2/p53. 2P2I HUNTER represents a useful tool for both academics and pharmaceutical companies to expand the scope of chemical libraries dedicated to protein -protein targets and to enhance hit rates in high-throughput experiments, thereby reducing the cost of screening campaigns. Briefly, molecules were first checked for errors in valence, coordination, aromaticity and covalently bound counter ions. Molecules were then standardized as follows: the largest fragment was kept, explicit hydrogens were removed, molecules were dearomatized, aromatized and neutralized, explicit hydrogens were added and finally the structures were cleaned in two dimensions. Major species at physiological pH 7.4 were then determined using cxcalc module.
Training set preparation
In order to reduce structural redundancy, the 52 inhibitors present in 2P2I DB were submitted to a diversity selection using the OptiSim module from Tripos that compares UNITY fingerprints of compounds. A Tanimoto coefficient of 80% was chosen as the similarity threshold, leading to a final active training dataset of 40 compounds. The same OptiSim procedure was applied to select a diverse set of 1089 compounds from the NCI Diversity set II (1364 compounds). Compounds with reactive groups and detergent compounds were removed manually to provide a final decoy dataset composed of 1018 molecules. The positive training set and decoy are available at http://2p2idb.cnrs-mrs. fr/2p2i_hunter.html.
Molecular descriptors
The 10 molecular descriptors used for machine-learning process (MW; number of multiple bonds; number of rings; number of rotatable bonds; number of donor atoms for H-bonds; number of acceptor atoms for H-bonds; unsaturation count; hydrophilic factor; topological polar surface area and ALogP) were computed with DRAGON v. 6 (http://www.talete.mi.it) on the charged compounds prepared with ChemAxon as described above. The 11th descriptor corresponded to the sum of hydrogen bond donors and acceptors. Molecules that generated errors in descriptors computation were discarded.
BCUT descriptors
The DiverseSolution module from Tripos was used to compute BCUT-based metrics [67] . The program performs a partitioning of the BCUT chemical space and determines which molecules from the studied set occupy each mapped cell. Cells coordinates were retrieved and submitted to a principal components analysis.
'Rule of 4' definition
The 'Ro4' is a rule of thumb that was derived from the distribution of molecular properties of PPI inhibitors in the 2P2I database [5, 55] . Small molecules follow the 'Ro4' if they obey three of the following properties: MW 400 Da, ALogP 4, number of rings more than or equal to 4 and number of hydrogen bond acceptors more than or equal to 4. It is worth pointing out that contrary to other rules, compounds need to exceed criteria to be compliant.
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Bioassay selection
Bioassays were retrieved from the PubChem Bioassay website that provides searchable descriptions of more than 600 000 bioassays (http://www.ncbi.nlm.nih.gov/pcassay). The detailed query is shown in the electronic supplementary material, figure S3 . Briefly, the keyword 'protein protein' was searched in AID corresponding to bioassay type summary. Then bioassays with both confirmatory and primary screenings were selected. Finally, bioassays were grouped by type summary. The 17 remaining bioassays were checked manually. Bioassays corresponding to enzymatic assays or cell-based were discarded leaving only two AID.
The name of the targets and the detailed description of assay methods for the blind validation with the in-house PPI bioassays could not be disclosed owing to confidentiality issues regarding the pharmaceutical partner.
Support vector machine model construction and validation
SVM algorithm implemented in the statistical software package R was used for model training [68] . Original data were mapped through a kernel function on to a higher dimensional space where the two sets are more easily separable with a linear classifier. The Caret library in R environment was used to perform SVM modelling. The positive or negative activity of our training set was typed as a factor variable to specify the classification mode of the problem. The RGB method was chosen as kernel function.
As a preprocessing treatment of data, each descriptor is centred around a mean of 0 and scaled to a variance equal to 1. The training is performed through a fivefold cross-validation procedure repeated 30 times with a random selection of the training and test sets at each time. The final optimal model was selected according to the average best performance of the ROC AUC (area under curve) statistical metric. The model training in RGB method consists of tuning two hyperparameters cost C and scaling function sigma along a grid of candidate values. The best final model was found with C ¼ 16 and s ¼ 0.006.
Enrichment factor
The enrichment factor which corresponds to the ratio of hit rates after and before filtration with the SVM model is given by the where EF is the enrichment factor obtained with the SVM filtered chemical library, Hit selected is the number of active compounds in the selected library, Hit total is the total number of active molecules in the library, N selected is the number of compounds selected by the SVM model and N total is the total number of compounds in the original (non-filtered) library.
Model validation
Statistical metrics used to assess the quality of the model are defined below.
where TP, true positive; TN, true negative; FN, false negative; FP, false positive. The accuracy measures the percentage of correctly predicted molecules altogether. Specificity and sensitivity reflect the ability to correctly predict inactive and active compounds, respectively.
Y-scrambling
In order to assess the reliability of the model, activity labels of the training set were randomly re-ordered by keeping positive/negative ratio. The two parameters cost and sigma remained unchanged and the same training configuration was applied, fivefold cross-validation repeated 30 times.
PCA analyses
PCA was performed using the library FactoMineR in R package [69] . All the 11 molecular descriptors were used to derive the principle components that defined the 2P2I chemical space, calculated on the whole training dataset. For the PCA of the external validation datasets and commercial libraries, properties of molecules were projected onto the first two principal components of the training set.
